Please login to the form below

Not currently logged in
Email:
Password:

Kiadis Pharma appoints chief medical officer

Jeroen Rovers joins the biopharma company from Ceronco Biosciences

edit-Jeroen-Rovers-2Biopharma company Kiadis Pharma has appointed Jeroen Rovers as its chief medical officer and he joins from Ceronco Biosciences where he was also CMO.

Prior to his position at Ceronco, Rovers was VP of medical affairs at Amsterdam-based Kiadis and had remained a consultant for the company until his re-appointment this week.

Rovers, whose areas of expertise include cell based therapeutics and advanced therapy medicinal products, has more that 15 years of experience in clinical development, during which time he held posts at Wyeth Pharmaceuticals Netherlands and Organon.

He said: “I am extremely excited to have the opportunity to rejoin Kiadis Pharma and be able to focus on its T-cell based immunology product ATIR. I believe ATIR is a truly innovative product and has the potential to become a key part of the next generation treatments of blood cancers.”

Kiadis develops T-cell immunology treatments for blood cancers and is currently sponsoring phase II trials for its lead product ATIR, a medicinal product enabling stem cell transplantations using partially mismatched family members as donors for patients suffering from blood cancer.

Manfred Ruediger, CEO of Kiadis Pharma, said: “Jeroen's medical and clinical expertise, coupled with business development connections, will be extremely useful given the stage of our phase II programme and the interest we have been seeing in our field.

“We feel he will continue to make a valuable addition to our team and help us to make ATIR a reality for patients and to develop it to its full potential.”

5th September 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics